2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid
| Title | Journal |
|---|---|
| Allopurinol induces innate immune responses through mitogen-activated protein kinase signaling pathways in HL-60 cells. | Journal of applied toxicology : JAT 20160901 |
| Allopurinol and oxypurinol promote osteoblast differentiation and increase bone formation. | Experimental cell research 20160315 |
| Febuxostat ameliorates doxorubicin-induced cardiotoxicity in rats. | Chemico-biological interactions 20150725 |
| Cardiovascular thromboembolic events associated with febuxostat: investigation of cases from the FDA adverse event reporting system database. | Seminars in arthritis and rheumatism 20130601 |
| Ultra-performance liquid chromatography-tandem mass spectrometry method for the determination of febuxostat in dog plasma and its application to a pharmacokinetic study. | Biomedical chromatography : BMC 20130201 |
| Xanthine oxidase inhibitor febuxostat as a novel agent postulated to act against vascular inflammation. | Anti-inflammatory & anti-allergy agents in medicinal chemistry 20130101 |
| Isocytosine-based inhibitors of xanthine oxidase: design, synthesis, SAR, PK and in vivo efficacy in rat model of hyperuricemia. | Bioorganic & medicinal chemistry letters 20121215 |
| The rheumatology of gout. | Advances in chronic kidney disease 20121101 |
| Febuxostat suppressed renal ischemia-reperfusion injury via reduced oxidative stress. | Biochemical and biophysical research communications 20121019 |
| Challenges associated with the management of gouty arthritis in patients with chronic kidney disease: a systematic review. | Seminars in arthritis and rheumatism 20121001 |
| Pharmacokinetics of febuxostat in healthy Chinese volunteers. | Arzneimittel-Forschung 20121001 |
| The effects of febuxostat on the pharmacokinetic parameters of rosiglitazone, a CYP2C8 substrate. | British journal of clinical pharmacology 20120801 |
| Payer decision-making with limited comparative and cost effectiveness data: the case of new pharmacological treatments for gout. | Evidence-based medicine 20120801 |
| Use of xanthine oxidase inhibitor febuxostat inhibits renal interstitial inflammation and fibrosis in unilateral ureteral obstructive nephropathy. | Clinical and experimental nephrology 20120801 |
| [Gout and other crystal-induced arthritides]. | Deutsche medizinische Wochenschrift (1946) 20120801 |
| Casebook consults: improving outcomes in gout (multimedia activity). | The American journal of medicine 20120801 |
| Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities. | American heart journal 20120701 |
| Pegloticase for treating refractory chronic gout. | Drugs of today (Barcelona, Spain : 1998) 20120701 |
| Recent advances in management of gout. | QJM : monthly journal of the Association of Physicians 20120501 |
| Identification of novel isocytosine derivatives as xanthine oxidase inhibitors from a set of virtual screening hits. | Bioorganic & medicinal chemistry 20120501 |
| The effects of xanthine oxidase inhibition by febuxostat on the pharmacokinetics of theophylline. | International journal of clinical pharmacology and therapeutics 20120501 |
| [Gout: an overview of available urate lowering therapies]. | Annales pharmaceutiques francaises 20120501 |
| Gout and organ transplantation. | Current rheumatology reports 20120401 |
| [Medication of the month. Febuxostat (Adenuric)]. | Revue medicale de Liege 20120401 |
| Hyperuricemia, gout and the kidney. | Current opinion in rheumatology 20120301 |
| Febuxostat hypersensitivity. | The Journal of rheumatology 20120301 |
| [Pharmacological sheet. Febuxostat, oral (Adenuric)]. | Journal de pharmacie de Belgique 20120301 |
| Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol. | Arthritis care & research 20120201 |
| Use of newly available febuxostat in a case of chronic tophaceous gout contraindicated to allopurinol and probenecid. | The Medical journal of Malaysia 20120201 |
| Dual energy computed tomography for quantification of tissue urate deposits in tophaceous gout: help from modern physics in the management of an ancient disease. | Rheumatology international 20120101 |
| An update on the pathology and clinical management of gouty arthritis. | Clinical rheumatology 20120101 |
| Can racial disparities in optimal gout treatment be reduced? Evidence from a randomized trial. | BMC medicine 20120101 |
| African American patients with gout: efficacy and safety of febuxostat vs allopurinol. | BMC musculoskeletal disorders 20120101 |
| Gout and the risk for incident heart failure and systolic dysfunction. | BMJ open 20120101 |
| The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age. | BMC geriatrics 20120101 |
| Different inhibitory potency of febuxostat towards mammalian and bacterial xanthine oxidoreductases: insight from molecular dynamics. | Scientific reports 20120101 |
| Redox proteomics identification of oxidatively modified myocardial proteins in human heart failure: implications for protein function. | PloS one 20120101 |
| Study of impurity carryover and impurity profile in Febuxostat drug substance by LC-MS/MS technique. | Journal of pharmaceutical and biomedical analysis 20111205 |
| [Treatment of gout]. | La Revue de medecine interne 20111201 |
| Comorbidities in gouty arthritis. | Journal of investigative medicine : the official publication of the American Federation for Clinical Research 20111201 |
| [Hyperuricemia, gout, pseudogout and concomitant diseases]. | Deutsche medizinische Wochenschrift (1946) 20111201 |
| Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects. | Nucleosides, nucleotides & nucleic acids 20111201 |
| 2011 Recommendations for the diagnosis and management of gout and hyperuricemia. | Postgraduate medicine 20111101 |
| 2011 recommendations for the diagnosis and management of gout and hyperuricemia. | The Physician and sportsmedicine 20111101 |
| Management of gout in the older adult. | The American journal of geriatric pharmacotherapy 20111001 |
| Catastrophic axial gout causing paraplegia in a patient with glycogen storage disease. | Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20111001 |
| Efficacy and safety of febuxostat in patients with hyperuricemia and gout. | Therapeutic advances in musculoskeletal disease 20111001 |
| [New therapeutic options for gout]. | Presse medicale (Paris, France : 1983) 20110901 |
| Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions. | The Journal of rheumatology 20110901 |
| Nickel-catalyzed C-H arylation of azoles with haloarenes: scope, mechanism, and applications to the synthesis of bioactive molecules. | Chemistry (Weinheim an der Bergstrasse, Germany) 20110829 |
| Gout and transplantation: new treatment option-same old drug interaction. | Transplantation 20110815 |
| Effect of acute xanthine oxidase inhibition on myocardial energetics during basal and very high cardiac workstates. | Journal of cardiovascular translational research 20110801 |
| Potential pharmacologic treatments for cystinuria and for calcium stones associated with hyperuricosuria. | Clinical journal of the American Society of Nephrology : CJASN 20110801 |
| The challenges of gout management in the elderly. | Drugs & aging 20110801 |
| [Gout - regardless of therapeutic options a 'forgotten' disease]. | Deutsche medizinische Wochenschrift (1946) 20110801 |
| Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. | Annals of the rheumatic diseases 20110701 |
| Febuxostat inhibition of endothelial-bound XO: implications for targeting vascular ROS production. | Free radical biology & medicine 20110701 |
| Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors. | The Journal of rheumatology 20110701 |
| [Febuxostat]. | Deutsche medizinische Wochenschrift (1946) 20110601 |
| Febuxostat efficacy in allopurinol-resistant tophaceous gout. | Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20110601 |
| A new standard of care? Studies on febuxostat in the management of hyperuricemia with and without gout. | Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20110601 |
| An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study. | Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20110601 |
| Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study. | Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20110601 |
| A repeated oral administration study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with impaired renal function in Japan: pharmacokinetic and pharmacodynamic study. | Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20110601 |
| Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study. | Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20110601 |
| An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study. | Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20110601 |
| Multicenter, open-label study of long-term administration of febuxostat (TMX-67) in Japanese patients with hyperuricemia including gout. | Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20110601 |
| Managing your patient with gout: a review of treatment options. | Postgraduate medicine 20110501 |
| Febuxostat methanol solvate. | Acta crystallographica. Section E, Structure reports online 20110501 |
| Developing potent human uric acid transporter 1 (hURAT1) inhibitors. | Journal of medicinal chemistry 20110428 |
| Febuxostat for treatment of chronic gout. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20110301 |
| Metabolism and excretion of [14C] febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, in healthy male subjects. | Journal of clinical pharmacology 20110201 |
| Febuxostat for the management of hyperuricaemia in patients with gout: a NICE single technology appraisal. | PharmacoEconomics 20110201 |
| Gout therapeutics: new drugs for an old disease. | Lancet (London, England) 20110108 |
| Renal function in gout: long-term treatment effects of febuxostat. | Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20110101 |
| Treatment of gout. | Internal medicine journal 20110101 |
| A case series of allopurinol-induced toxic epidermal necrolysis. | Indian journal of dermatology 20110101 |
| Tophaceous gout and renal insufficiency: a new solution for an old therapeutic dilemma. | Case reports in medicine 20110101 |
| Renal co-morbidity in patients with rheumatic diseases. | Arthritis research & therapy 20110101 |
| The Relation between Fructose-Induced Metabolic Syndrome and Altered Renal Haemodynamic and Excretory Function in the Rat. | International journal of nephrology 20110101 |
| Multiarticular chronic tophaceous gout with severe and multiple ulcerations: a case report. | Journal of medical case reports 20110101 |
| Combinatorial effect of non-steroidal anti-inflammatory drugs and NF-κB inhibitors in ovarian cancer therapy. | PloS one 20110101 |
| The role of the NLRP3 inflammasome in gout. | Journal of inflammation research 20110101 |
| Hyperuricemia is independently associated with coronary heart disease and renal dysfunction in patients with type 2 diabetes mellitus. | PloS one 20110101 |
| Calciphylaxis presenting in early chronic kidney disease with mixed hyperparathyroidism. | International journal of nephrology and renovascular disease 20110101 |
| Emerging role of rasburicase in the management of increased plasma uric acid levels in patients with hematologic malignancies. | Journal of blood medicine 20110101 |
| [Current management of gout]. | Acta medica portuguesa 20110101 |
| Febuxostat: a novel agent for management of hyperuricemia in gout. | Indian journal of pharmaceutical sciences 20110101 |
| Crystal arthropathies: recognizing and treating 'the gouch'. | Primary care 20101201 |
| Managing gout: how is it different in patients with chronic kidney disease? | Cleveland Clinic journal of medicine 20101201 |
| Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. | Clinical therapeutics 20101201 |
| [Therapy of acute gout attack. It need not always be NSAID]. | MMW Fortschritte der Medizin 20101125 |
| The current state of care in gout: Addressing the need for better understanding of an ancient disease. | Journal of the American Academy of Nurse Practitioners 20101101 |
| Febuxostat, a nonpurine selective inhibitor of xanthine oxidase: a promising medical therapy for chronic heart failure? | Chinese medical journal 20100901 |
| International position paper on febuxostat. | Clinical rheumatology 20100801 |
| Managing gout in the primary care setting: what you and your patients need to know. | The American journal of medicine 20100801 |
| Febuxostat for gout. | Drug and therapeutics bulletin 20100701 |
| Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a non-purine selective inhibitor of xanthine oxidase. | British journal of clinical pharmacology 20100701 |
| Synthesis of some 5-phenylisoxazole-3-carboxylic acid derivatives as potent xanthine oxidase inhibitors. | European journal of medicinal chemistry 20100601 |
| High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up. | Diabetes care 20100601 |
| Urate-lowering therapy for gout: focus on febuxostat. | Pharmacotherapy 20100601 |
| Delayed treatment effects of xanthine oxidase inhibition on systolic overload-induced left ventricular hypertrophy and dysfunction. | Nucleosides, nucleotides & nucleic acids 20100601 |
| New agents for the treatment of gout and hyperuricemia: febuxostat, puricase, and beyond. | Current rheumatology reports 20100401 |
| Progress in the pharmacotherapy of gout. | Current opinion in rheumatology 20100301 |
| Febuxostat provides new gout treatment option. | The Nurse practitioner 20100301 |
| Update on gout and hyperuricemia. | International journal of clinical practice 20100201 |
| New Drugs2010, PART 1. | Nursing 20100201 |
| Update on gout: new therapeutic strategies and options. | Nature reviews. Rheumatology 20100101 |
| Management of hyperuricemia in gout: focus on febuxostat. | Clinical interventions in aging 20100101 |
| The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. | Arthritis research & therapy 20100101 |
| [The clinical picture of gout is changing]. | Duodecim; laaketieteellinen aikakauskirja 20100101 |
| Advances in gout: some answers, more questions. | Arthritis research & therapy 20100101 |
| New advances in the treatment of gout: review of pegloticase. | Therapeutics and clinical risk management 20100101 |
| [Gout and comorbidities associated with hyperuricemia]. | Annales Academiae Medicae Stetinensis 20100101 |
| Advances in the management of gout: critical appraisal of febuxostat in the control of hyperuricemia. | International journal of nephrology and renovascular disease 20100101 |
| New and improved strategies for the treatment of gout. | International journal of nephrology and renovascular disease 20100101 |
| [Crystal-induced activation of the inflammasome: gout and pseudogout]. | Zeitschrift fur Rheumatologie 20091101 |
| Approach to the treatment of hyperuricemia. | Medicine and health, Rhode Island 20091101 |
| Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout. | Clinical therapeutics 20091101 |
| 2-[3-Cyano-4-(2-methyl-prop-oxy)phen-yl]-4-methyl-thia-zole-5-carboxylic acid pyridine solvate. | Acta crystallographica. Section E, Structure reports online 20091101 |
| Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal. | Health technology assessment (Winchester, England) 20091001 |
| Gout Study Group: update on hyperuricemia and gout. | Joint, bone, spine : revue du rhumatisme 20090701 |
| Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. | The Journal of rheumatology 20090601 |
| Gout--what are the treatment options? | Expert opinion on pharmacotherapy 20090601 |
| Febuxostat (Uloric) for chronic treatment of gout. | The Medical letter on drugs and therapeutics 20090518 |
| Febuxostat: a new treatment for hyperuricaemia in gout. | Rheumatology (Oxford, England) 20090501 |
| Nickel-catalyzed biaryl coupling of heteroarenes and aryl halides/triflates. | Organic letters 20090416 |
| A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout. | Current rheumatology reports 20090401 |
| New gout treatment approved. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20090401 |
| Febuxostat: a new agent for lowering serum urate. | Drugs of today (Barcelona, Spain : 1998) 20090401 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20090401 |
| Febuxostat: new drug. Hyperuricaemia: risk of gout attacks. | Prescrire international 20090401 |
| Febuxostat treatment for gout: what the clinician needs to know. | Therapeutic advances in musculoskeletal disease 20090401 |
| Febuxostat. | Nature reviews. Drug discovery 20090301 |
| Update on emerging urate-lowering therapies. | Current opinion in rheumatology 20090301 |
| Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. | Rheumatology (Oxford, England) 20090201 |
| Role of urate, xanthine oxidase and the effects of allopurinol in vascular oxidative stress. | Vascular health and risk management 20090101 |
| New drugs: Febuxostat, lacosamide, and rufinamide. | Journal of the American Pharmacists Association : JAPhA 20090101 |
| Gout. Novel therapies for treatment of gout and hyperuricemia. | Arthritis research & therapy 20090101 |
| Gout. Hyperuricemia and cardiovascular disease: how strong is the evidence for a causal link? | Arthritis research & therapy 20090101 |
| The role of urate and xanthine oxidase in vascular oxidative stress: future directions. | Therapeutics and clinical risk management 20090101 |
| Febuxostat: the evidence for its use in the treatment of hyperuricemia and gout. | Core evidence 20090101 |
| Febuxostat in the management of hyperuricemia and chronic gout: a review. | Therapeutics and clinical risk management 20081201 |
| Gout management: let's get it right this time. | Arthritis and rheumatism 20081115 |
| Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. | Arthritis and rheumatism 20081115 |
| Xanthine oxidase inhibition with febuxostat attenuates systolic overload-induced left ventricular hypertrophy and dysfunction in mice. | Journal of cardiac failure 20081101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20081001 |
| The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. | Journal of clinical pharmacology 20080901 |
| Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. | Nucleosides, nucleotides & nucleic acids 20080601 |
| In vitro drug-drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition. | Xenobiotica; the fate of foreign compounds in biological systems 20080501 |
| Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20080401 |
| Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome. | American journal of physiology. Renal physiology 20080401 |
| [Inhibitors of xanthine oxidoreductase]. | Nihon rinsho. Japanese journal of clinical medicine 20080401 |
| [New antihyperuricemic medicine: febuxostat, Puricase, etc]. | Nihon rinsho. Japanese journal of clinical medicine 20080401 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20080401 |
| Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects. | British journal of clinical pharmacology 20080301 |
| Refractory gout: what is it and what to do about it? | Current opinion in rheumatology 20080301 |
| Chronic xanthine oxidase inhibition following myocardial infarction in rabbits: effects of early versus delayed treatment. | Life sciences 20080227 |
| Crystal structures of mammalian xanthine oxidoreductase bound with various inhibitors: allopurinol, febuxostat, and FYX-051. | Journal of Nippon Medical School = Nippon Ika Daigaku zasshi 20080201 |
| Effect of febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyperuricemia. | Nephron. Physiology 20080101 |
| A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients? | Drug safety 20080101 |
| Febuxostat. | Drugs 20080101 |
| Febuxostat: a viewpoint by H. Ralph Schumacher Jr and Lan X. Chen. | Drugs 20080101 |
| Febuxostat : a viewpoint by Naomi Schlesinger. | Drugs 20080101 |
| Febuxostat : a viewpoint by N. Lawrence Edwards. | Drugs 20080101 |
| Developments in the scientific and clinical understanding of gout. | Arthritis research & therapy 20080101 |
| Assessment of outcome in clinical trials of gout--a review of current measures. | Rheumatology (Oxford, England) 20071201 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20071201 |
| [Crystal-induced arthritis--old but important]. | Zeitschrift fur Rheumatologie 20070701 |
| Tumor lysis syndrome. | Seminars in thrombosis and hemostasis 20070601 |
| Uricase and other novel agents for the management of patients with treatment-failure gout. | Current rheumatology reports 20070601 |
| Emerging therapies in the long-term management of hyperuricaemia and gout. | Internal medicine journal 20070401 |
| Therapeutic advances in gout. | Current opinion in rheumatology 20070301 |
| Febuxostat: a novel non-purine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in gout. | Recent patents on inflammation & allergy drug discovery 20070201 |
| Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout. | International journal of medical sciences 20070101 |
| Hyperuricemia and gout: new insights into pathogenesis and treatment. | Bulletin of the NYU hospital for joint diseases 20070101 |
| Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout. | The Annals of pharmacotherapy 20061201 |
| Case 8: initiation of urate-lowering therapy for standard advanced gout. | The American journal of medicine 20061101 |
| Acute effects of febuxostat, a nonpurine selective inhibitor of xanthine oxidase, in pacing induced heart failure. | Journal of cardiovascular pharmacology 20061101 |
| Gout Assessment Questionnaire: Initial results of reliability, validity and responsiveness. | International journal of clinical practice 20061001 |
| [Febuxostat versus allopurinol for hyperuricemia]. | Medizinische Monatsschrift fur Pharmazeuten 20061001 |
| Pharmacokinetic interactions of concomitant administration of febuxostat and NSAIDs. | Journal of clinical pharmacology 20060801 |
| Febuxostat for prevention of gout attacks. | Issues in emerging health technologies 20060801 |
| Gout's not just for the gluttonous. | The Johns Hopkins medical letter health after 50 20060601 |
| New developments in clinically relevant mechanisms and treatment of hyperuricemia. | Current rheumatology reports 20060601 |
| Is febuxostat a more effective treatment for hyperuricemia and gout than allopurinol? | Nature clinical practice. Rheumatology 20060501 |
| Febuxostat versus allopurinol for gout. | The New England journal of medicine 20060406 |
| Febuxostat versus allopurinol for gout. | The New England journal of medicine 20060406 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20060401 |
| Newer therapeutic approaches: gout. | Rheumatic diseases clinics of North America 20060201 |
| [Gout]. | Revue medicale suisse 20060111 |
| The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. | Journal of clinical pharmacology 20060101 |
| A concise history of gout and hyperuricemia and their treatment. | Arthritis research & therapy 20060101 |
| Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics. | Arthritis research & therapy 20060101 |
| Advances in the management of gout and hyperuricaemia. | Scandinavian journal of rheumatology 20060101 |
| Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects. | Clinical pharmacokinetics 20060101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20060101 |
| Pathophysiology, clinical presentation and treatment of gout. | Drugs 20060101 |
| Metabolic diseases: gout. | Clinics in dermatology 20060101 |
| Febuxostat compared with allopurinol in patients with hyperuricemia and gout. | The New England journal of medicine 20051208 |
| Febuxostat--treatment for hyperuricemia and gout? | The New England journal of medicine 20051208 |
| An update on the treatment options for gout and calcium pyrophosphate deposition. | Expert opinion on pharmacotherapy 20051101 |
| Febuxostat (Teijin/Ipsen/TAP). | Current opinion in investigational drugs (London, England : 2000) 20051101 |
| Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout. | Expert opinion on investigational drugs 20050701 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20050601 |
| Recent advances in the management of gout and hyperuricemia. | Current opinion in rheumatology 20050501 |
| Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. | Life sciences 20050304 |
| Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. | Arthritis and rheumatism 20050301 |
| Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. | American journal of therapeutics 20050101 |
| Y-700 [1-[3-Cyano-4-(2,2-dimethylpropoxy)phenyl]-1H-pyrazole-4-carboxylic acid]: a potent xanthine oxidoreductase inhibitor with hepatic excretion. | The Journal of pharmacology and experimental therapeutics 20041101 |
| Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers. | Nucleosides, nucleotides & nucleic acids 20041001 |
| PK/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment. | Nucleosides, nucleotides & nucleic acids 20041001 |
| Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase/xanthine dehydrogenase (NPSIXO) in patients with gout and/or hyperuricemia. | Nucleosides, nucleotides & nucleic acids 20041001 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20040901 |
| Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase. | Current rheumatology reports 20040601 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20031201 |
| An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. | The Journal of biological chemistry 20030117 |
| [Development antihyperuricemic candidates]. | Nihon rinsho. Japanese journal of clinical medicine 20030101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20030101 |